10x Genomics (TXG) announced that it has reached a settlement agreement with Bruker (BRKR), successfully resolving all outstanding worldwide patent litigation and disputes between the two companies. As part of the settlement, 10x expects that Bruker will pay $68M in equal quarterly installments between the third quarter of 2025 and the second quarter of 2026, as well as ongoing royalties on sales of its spatial biology products through the life of the licensed patents. The settlement includes global patent cross-licenses and a complete withdrawal of all legal proceedings, including those in the United States, Germany and before the European Unified Patent Court.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- Bruker, 10x Genomics reach final settlement to resolve patent disputes
- 10x Genomics price target lowered to $12 from $14 at UBS
- 10x Genomics Faces Market Challenges and Uncertainty, Leading to Hold Rating
- 10x Genomics price target lowered to $15 from $18 at Canaccord
- 10X Genomics Faces Mixed Outlook Amid Funding Uncertainties